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Background. Antiretroviral therapy (ART) has led to increased survival of children with vertically acquired
human immunodeﬁciency virus infection. Signiﬁcant morbidity arises from respiratory symptoms, but aetiology
and pulmonary function abnormalities have not been systematically studied.
Methods. Human immunodeﬁciency virus-positive children aged 8–16 years were systematically recruited
within clinics in Blantyre, Malawi. Clinical review, quality of life assessment, spirometry, and chest radiography
were performed.
Results. One hundred sixty participants had a mean of age 11.1 (range, 8–16) years and 50.0% were female.
Cough was present in 60 (37.5%) participants, and 55 (34.4%) had moderate or severe dyspnoea. Thirty-four
(22.1%) participants had digital clubbing. Thirty-three (20.6%) participants were hypoxic at rest. One hundred
eighteen (73.8%) of the children were receiving ART; median CD4 count was 698 cells/µL in these compared
with 406 cells/µL in ART-naive individuals (P < .001). From 145 spirometry traces (90.6%), mean forced
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were 1.06 and 0.89 standard deviations
below predicted mean, respectively. Twenty-one (14.5%) traces demonstrated obstructive defects and 26
(17.9%) reduced FVC. Lung function abnormality was not associated with any clinical ﬁndings. Of the 51
individuals with abnormal lung function, the mean increase in FEV1 after salbutamol was 3.8% (95%
conﬁdence interval, 0.02–7.53). “Tramlines” and ring shadows were seen on chest radiographs in over half
of cases.
Conclusions. Symptoms of chronic lung disease were highly prevalent with 2 main clinical phenotypes:
“cough” and “hypoxia”. Lung function abnormalities are common, poorly responsive to bronchodilators, and
apparent throughout the age range of our cohort. Pathological causes remain to be elucidated. Cough and
hypoxic phenotypes could be a useful part of diagnostic algorithms if further validated.
Key words. case deﬁnition; chronic lung disease; HIV; infectious disease transmission; respiratory function
tests; vertical.
An estimated 3.2 million children are living with human
immunodeﬁciency virus (HIV) [1], most of whom live in
sub-Saharan Africa. Approximately 199,000 children
were newly infected in 2013. Scale-up of antiretroviral
therapy (ART) provision is likely to contribute to improve-
ments in survival amongst children with HIV [2].However,
in sub-Saharan Africa, only 22% of HIV-positive children
are receiving ART, lagging behind 39% coverage in adults
[1]. Prevention of vertical infection through Prevention of
Mother-to-Child Transmission (PMTCT) program is effec-
tive, but worldwide coverage requiring ART has been sub-
optimal. An estimated 1%–3% of all 10-year-olds in
Southern Africa are HIV-infected, long-term survivors,
with 68% of eligible women receiving ART as PMTCT
in 2013 compared with 33% 5 years previously [1]. In a
hospital-based study from Zimbabwe, advanced HIV
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infection was the single most common cause of admission
and death in adolescents [3].
With longer survival, lung effects of HIV become more
prominent. Human immunodeﬁciency virus-infected chil-
dren in sub-Saharan Africa are subject to frequent pulmo-
nary infections [4], and they commonly develop chronic
cough in older childhood. In a Zimbabwean study of 116
HIV-infected adolescents receiving HIV care, dyspnoea
was often disabling, and resting hypoxia or desaturation
at submaximal exercise was present in 40% of patients
[5]. Chest radiographs were abnormal in two thirds of pa-
tients, characterized by ring and tramline opacities, whose
presence is unrelated to clinical symptoms. High-resolution
computerized tomography (HRCT) scans suggested small
airways disease as the most common cause of infection;
however, bronchodilator response was not assessed [6].
Despite this, data on symptoms of chronic lung disease
(CLD) and lung function testing, particularly in developing
countries, are lacking.
We describe the burden and clinically useful phenotypes
of CLDs, and we assess the bronchodilator response
with inhaled beta-agonist therapy in HIV-infected
children aged 8 to 16 receiving HIV care in Blantyre,
Malawi.
METHODS
Participants
Participants were recruited from outpatient HIV clinics in
Queen Elizabeth Central Hospital, Blantyre between July
and December 2011. The ﬁrst 3 eligible patients per day
were included. Patients were not eligible for recruitment
if they (1) resided outside urban Blantyre, (2) were current-
ly taking tuberculosis (TB) treatment, (3) had Kaposi’s sar-
coma, (4) reported acute respiratory symptoms (1 week
of any one or more of fever, purulent sputum, pleuritic
chest pain), or (5) required emergent hospitalization.
At baseline, we assessed medical history, symptoms,
quality of life, and functional status by standardized verbal
questionnaires administered in the local language.
Examination included assessment of ﬁnger clubbing,
growth, and World Health Organization (WHO) clinical
staging of HIV disease. CD4 count was performed, and
TB smear and culture were done in all participants who
could spontaneously expectorate. Participants performed
a 200 meter submaximal walk test, unless contraindicated
due to resting hypoxia (SpO2 <92%) or tachypnoea (>24/
minutes). Within 2 weeks, participants had spirometry un-
less there was evidence of TB or acute respiratory illness
[7]. Chest radiographs were reported by 2 independent cli-
nicians using a standardized scoring system [6], with dis-
crepancies resolved by consensus.
Quality of Life Assessment
In the absence of a disease-speciﬁc tool, quality of life was
assessed using the Cystic Fibrosis Questionnaire-Revised
([CFQ-R] for 6- to 13-year-olds and their carers in paral-
lel). These incorporate 9 quality of life domains (physical,
school, vitality, emotion, social, body image, eating, treat-
ment burden, health perception) and 3 symptom domains
(respiratory, digestion, weight). Translation was done by 2
independent translators, collation by consensus, and back-
translation for accuracy [8].
Spirometry and Radiology
Spirometry was performed according to ATS/ERS guide-
lines [9]by experienced nursing staff and a respiratory phy-
sician. Forced exhalation following maximal inspiration
was recorded while seated using an EasyOne World spiro-
meter (ndd, Zurich, Switzerland). Up to 8 trials were
recorded, and these were assessed by 2 clinicians indepen-
dently for quality. The best forced expiratory volume in 1
second (FEV1) and forced vital capacity (FVC) values from
3 admissible traces were included for analysis. Primary ref-
erence values were taken from the Global Lung Initiative
[10], using the 5th centile of the reference population as
the lower limit of normal ([LLN] 1.64 standard deviation
[SD] below the mean). Results of FEV1, FVC, FEV1:FVC,
and forced expiratory ﬂow at 25%–75% are reported as
residual SDs (z-scores). Participants with FEV1 and
FEV1:FVC ratio of less than the LLNwere classiﬁed as hav-
ing obstructive spirometry. Where FVCwas reduced below
LLN and FEV1:FVC was not, we recorded “reduced FVC”
because wewere unable to measure total lung capacities. In
participants with abnormal spirometry, testing was repeat-
ed after nebulized salbutamol (2.5 mg via face mask).
Reversibility was deﬁned as improvement of 12% in
best FEV1 or FVC [9]. Participants meeting this criterion
were prescribed inhaled salbutamol via metered dose inhal-
er with an Aerochamber device (GSK, UK), 200 µg at least
twice a day, and additionally when symptomatic. These
participants returned for clinical reassessment after
4 weeks of treatment.
Secondary interpretation used a locally derived reference
range [11], with LLN of 80% predicted. Results are pre-
sented as “percentage of normal” given uncertain popula-
tion standard errors.
Laboratory Methods
CD4 counts were determined by ﬂow cytometry (BD
FACSCount, Franklin Lakes, NJ). Participants with cough
were asked to provide 2 sputum specimens. Concentrated
decontaminated sputum specimens were examined with
auramine and cultured using Mycobacterial Growth
Indicator Tubes (MGIT; BD, Franklin Lakes, NJ). Positive
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mycobacterial cultures were conﬁrmed by Ziehl-Neelsen stain-
ing and speciated using the Hain assay (Hain LifeScience
GmbH, Germany).
Ethical Approval
Ethical approval was obtained from the College of
Medicine Research Ethics Committee, Malawi (P.02/11/
1039) and the London School of Hygiene and Tropical
Medicine Ethics Committee (approval #5964). Informed
written or witnessed thumbprint participant assent and pa-
rental or guardian consent were required for recruitment.
Analysis
Univariable associations of abnormal lung function were
assessed using logistic regression, with predictors at
P < .10 taken forward to a multivariable model in addition
to age and sex.
Exploratory analysis was used to compare different pro-
totype deﬁnitions of CLD, including 2-way associations
between individual variables, aiming for a deﬁnition that
could be applied in outpatient clinics where investigations
are limited to oximetry and symptom screening. We as-
sessed univariable relationships, looking for a clinically
useful phenotype. Multivariable logistic regression was
then used to identify independent variables independently
associated with these phenotypes. A hierarchical approach
to modeling (2 levels: distal and proximal) was used to ac-
count for factors that affect the lungs indirectly and
directly, respectively [12]. Distal (indirect) factors were as
follows: stunting, orphanhood, and variables selected a
priori for inclusion including sex, age, ART, and CD4
count. Proximal (direct) factors included symptoms, phys-
iological observations, and radiographic and spirometric
abnormality. Participants with positive Mycobacterium
tuberculosis culture were excluded from case deﬁnition
analyses. Statistical analyses were conducted with Stata
version 12 (StataCorp, College Station, TX).
RESULTS
The ﬂow and baseline characteristics of the 160 partici-
pants are shown in Figure 1 and Table 1, respectively. All
children in the study were black African, with a mean age
of 11.1 years (SD = 2.1). One hundred fourteen (71.7%)
were established on ART, and a further 46 (28.3%) had
an established diagnosis of HIV but were not eligible
for ART according to national guidelines. Median CD4
counts in these groups were 698 cells/µL and 406 cells/
µL, respectively (P < .001, Wilcoxon rank-sum test).
Perinatal acquisition of HIV was assumed after a system-
atic review of participants’ risk factors: 16 (10.3%) partic-
ipants had received blood transfusion; 11 (6.9%)
participants had previous surgery; 53 (33.1%) participants
had injections outside the healthcare setting, including
escariﬁcation; 3 (1.9%) participants reported sexual
abuse; none reported other sexual activity. Eighty-nine
(56%) participants had no risk factors other than maternal
orphanhood or known HIV infection, although reported
factors for other transmission routes were higher than in
the Zimbabwe study [13]. Previous respiratory complaints
were common: 30 (18.8%) participants had been treated
for TB; 20 (12.5%) participants had been treated for asth-
ma; and 13 (8%) participants were treated for chest infec-
tion requiring hospitalization. Household air pollution
was common. Seventy-six (47.5%) and 117 (73.1%) of
households used biomass fuel as the predominant energy
source for lighting and cooking, respectively. Passive smok-
ing was reported in 23 (14.5%) participants.
It is worth noting that 91 (56.9%) participants had 1 or
more of the following symtoms: cough; moderate or severe
dyspnoea New York Heart Association ([NYHA] grade III
and IV); wheeze. Of those with previous pulmonary TB,
6 (3.8%) had received more than 2 courses. In the preceding
year, 34 (21.3%) had used antibiotics for a lower respiratory
tract infection: 17 (10.6%) had received multiple courses.
Quality of Life
Participants reported high quality of life in 6 domains (me-
dian scores of 88.9–100.0 for emotional, eating, body
image, treatment burden, respiratory, and digestion),
where 100 is the maximum score. Social and physical
activity domains had the lowest median scores of 57.1
(interquartile range [IQR], 47.6–57.1) and 83.3 (IQR,
55.6–100.0), respectively.
Developing a Case Deﬁnition and Phenotypes of Chronic
Lung Disease
An association matrix was used to investigate potential case
deﬁnitions (Supplementary Table 1). Two patients with ac-
tive TB were excluded from this analysis. Two candidate
phenotypes were postulated: one characterized by cough
(37.5%; 95% conﬁdence interval [CI], 30.0%–45.1%)
and the other by hypoxia or desaturation at submaximal ex-
ercise (38.8%; 95%CI, 31.1–46.4%). Although thesemight
be expected to commonly coexist, only 22 (13.8%; 95%CI,
8.4%–19.1%) participants had both. There was lack of
agreement between these 2 variables over that expected by
chance alone (expected agreement 52.8%, observed agree-
ment 51.3%, kappa =−3.3%). Therefore, we further char-
acterized those 2 proposed phenotypes (CLD cough and
CLD hypoxia) (see Figure 3). Table 2 summarizes univari-
able and multivariable analysis of risk factors for chronic
cough and hypoxia or desaturation individually.
Chronic lung disease cough was not associated with any
indirect factors, but it was signiﬁcantly associated with
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wheeze (odds ratio [OR] = 11.47; 95% CI, 2.44–53.83),
abnormal chest radiograph (OR = 3.00; 95% CI, 1.15–
7.85), and abnormal spirometry (OR = 2.61; 95% CI,
1.29–5.28). Participants with higher levels of exercise
tolerance as measured by CFQ-R physical domain had
reduced odds of CLD cough (OR = 0.98; 95% CI, 0.97–
0.99). After multivariable analysis, wheeze (OR = 6.94;
95% CI, 1.38–34.95; P = .019), CFR-Q physical domain
(OR = 0.98; 95% CI, 0.97–1.00; P = .017), and abnormal
chest radiograph (OR = 3.43; 95% CI, 1.01–7.85;
P = .048) remained signiﬁcant.
Chronic lung disease hypoxia had more limited univariate
predictors: only ﬁnger clubbing (OR= 2.28; 95% CI, 1.04–
4.99) and respiratory rate (OR = 3.00; 95% CI, 1.52–5.92).
Only resting tachypnoea remained signiﬁcant in multivari-
able modeling adjusted for a priori variables. There was
Figure 1. Study ﬂowchart. Flow diagram illustrates participant retention and quality of spirometry throughout the study. CXR, chest x-ray.
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weak evidence for the association of CD4 <100 cell/µL
and CLD hypoxia (OR = 3.87; 95% CI, 0.99–16.39;
P = .051) compared with children having a CD4 count of
350 or more.
Spirometry
Spirometry results for 145 participants are summarized in
Table 3 and Figure 2A. Median FEV1 and FVC were re-
duced compared with international reference ranges
(1.31 SD and 0.89 SD below expected, respectively).
Categorically, 90 (62.1%) participants had normal spiro-
metry, 26 (17.9%) participants had obstructive defects,
and 29 (20.0%) participants had reduced FVC. Fewer in-
dividuals were classiﬁed as having abnormalities using
local compared with international reference range (43 vs
55). Within our cohort, FEV1 z-score did not signiﬁcantly
decline with age (Figure 2B; r2 = 0.026; P = .054).
Fifty-ﬁve participants had abnormal spirometry, 47 of
whom adequately completed postbronchodilator testing.
Median change in FEV1 was 2.9% (IQR, −4.3 to 9.2).
Reversibility threshold of 12% increase was met in 7
(33.3%) of those with obstructive abnormalities and 8
(30.8%) with reduced FVC. When reviewed 4 weeks after-
wards, despite being given salbutamol, only 2 participants
continued to use their inhaler, and none reported sympto-
matic improvement.
Table 1. Demographic and Clinical Characteristics
Characteristic n (%) unless stated
Age, median years (IQR) 11.1 (9.5–12.4)
Sex, female (%) 80 (50.0%)
Age at HIV diagnosis, median years (IQR) 7.9 (5.8–9.8)
Child aware of HIV diagnosis,a n (%) 65 (41.1)
CD4 count,c median cells/µL (IQR) 572 (370–876)
Taking cotrimoxazole prophylaxis, n (%) 159 (99.4%)
On ART,a n (%) 114 (71.7%)
Duration of ART,b median years (IQR) 3.5 (1.3–4.6)
Chest infection in preceding year, n (%) 30 (18.8%)
Cough, n (%) 60 (37.5)
Sputum produced, n (%) 32 (20.0)
Wheezing in last 12 months, n (%) 13 (8.1)
Breathlessness (NYHA class), n (%)
0 85 (53.1)
1 9 (5.6)
2 11 (6.9)
3 9 (5.6)
4 46 (28.8)
Stunted [HFA z 2], n (%) 89 (55.6%)
WFH z-score, mean (SD) −0.82 (±1.09)
Finger clubbing, n (%) 34 (22.1)
Resting pulse rate, median min−1 (IQR) 87.0 (76.0–98.5)
Resting tachypnoea [>24/min], n (%) 57 (35.6)
Resting hypoxia [SpO2 <92%], n (%) 33 (20.6)
Normoxemia but desaturates >4%, n (%) 29 (18.1)
Abbreviations: ART, antiretroviral therapy; HFA, height for age; HIV, human
immunodeficiency virus; IQR, interquartile range; NYHA, New York Heart
Association breathlessness scale; SD, standard deviation; WFH, weight for
height.
aContinuous data are represented as median (IQR).
bMissing data n = 1.
cUnknown n = 15; data unavailable n = 3.
Table 2. Risk Factors for Chronic Lung Disease Defined by Presence of Cough and Hypoxia
Characteristic Presence of Cough Presence of Hypoxia or Desaturation
Univariate
OR (95% CI) P
Multivariatea
OR (95% CI) P
Univariate
OR (95% CI) P
Multivariatea
OR (95% CI) P
Distal (Indirect) Factors
Sex, female 0.72 (0.38–1.38) .322 1.24 (0.65–2.35) .514
Age, years 0.99 (0.84–1.16) .883 1.00 (0.81–1.23) .98 0.97 (0.82–1.14) .68 0.95 (0.79–1.13) .54
Orphaned (1+ parent died) 0.65 (0.34–1.24) .192 1.36 (0.71–2.6) .348
HFA, z-score 0.85 (0.64–1.12) .25 0.90 (0.68–1.18) .451
WFH, z-score 0.96 (0.71–1.30) .798 0.91 (0.67–1.22) .515
ART prescribed 0.91 (0.45–1.84) .788 0.79 (0.34–1.83) .59 0.64 (0.32–1.28) .207 0.83 (0.35–1.96) .67
Age at which ART started, years 0.94 (0.82–1.08) .372 0.92 (0.8–1.06) .227
CD4c <100 1.93 (0.53–7.04) .32 4.03 (0.99–16.39) .051 3.87 (0.91–16.42) .066
100–199 1.93 (0.53–7.04) .32 1.72 (0.47–6.30) .41
200–349 1.50 (0.52–4.31) .45 0.79 (0.26–2.41) .67
>349 1.00 – 1.00 –
Proximal (Direct) Factors
Previous TB 1.49 (0.69–3.22) .316 1.51 (0.7–3.24) .295
Smoker in household 0.44 (0.15–1.25) .104 0.49 (0.18–1.33) .145
NYHA grade 3 or 4 1.65 (0.84–3.24) .148 0.77 (0.39–1.52) .45
Wheeze 11.47 (2.44–53.83) <.001 6.94 (1.38–34.95) .019 0.44 (0.12–1.66) .198
CFQ-R physical domain 0.98 (0.97–0.99) <.001 0.98 (0.97–1.00) .017 1.00 (0.99–1.01) .623
Clubbing 1.19 (0.54–2.63) .666 2.28 (1.04–4.99) .038 1.28 (0.50–3.25) .60
Respiratory rate, >25/min at rest 0.98 (0.50–1.93) .948 3.00 (1.52–5.92) .001 2.39 (1.06–5.38) .032
Pulse rate, beats/min 1.01 (0.99–1.03) .185 1.00 (0.98–1.01) .585
CXR abnormalityb 3.00 (1.15–7.85) .023 3.43 (1.01–11.65) .048 1.04 (0.4–2.7) .941
Abnormal spirometry 2.61 (1.29–5.28) .007 2.09 (0.94–4.66) .072 1.65 (0.83–3.28) .153
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CFQ-R, Cystic Fibrosis Questionnaire-Revised; CXR, chest x-ray; HFA, height for age; NYHA,
New York Heart Association breathlessness scale; OR, odds ratio; TB, tuberculosis; WFH, weight for height.
aAdjusted for priori variables: age, sex, and being on ART and significant distal and proximal variables.
bDefined here as consolidation, volume loss, or lymphadenopathy because other findings were nondiscriminatory.
cComparator population is those with CD4 >349. Participants diagnosed with pulmonary tuberculosis are not included in this analysis.
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Chest Radiograph Abnormalities
The majority of radiographs had at least 1 abnormality
(n = 110, 68.8%). Upper or lower zone preponderance
were uncommon (n = 12, 10.9% and n = 13, 11.8%, respec-
tively) compared with mid-zone abnormality. The most fre-
quent abnormality was ring or tramlining pattern (n = 90,
56.3%). Two abnormalities (airspace shadowing and vol-
ume loss) were discriminatory for both CLD phenotypes
(Table 2) and spirometric abnormality (Supplementary
Table 3). Air space shadowing (n = 10, 6.3%) and loss of
volume (n = 3, 1.9%) were associated with reduced FEV1
(P = .0032 and P = .010, respectively). Other radiographic
ﬁndings were not signiﬁcantly associated with differences
in FEV1 or FVC z-score.
Clinical Associations of Lung Function
Potential associates of abnormal spirometry were investi-
gated (Supplementary Data, Table 2). Only 1 strong
Table 3. Spirometric Indices*
Baseline Spirometry (n = 145) GLI Reference [10] Local Reference
FEV1 −1.31 (−2.10 to −0.27)† 92.2 (79.5 to 104.6)‡
FVC −0.89 (−1.91 to −0.18)† 93.9 (81.8 to 104.2)‡
FEV1/FVC −0.27 (−1.21 to 0.35)† 87.9 (82.1 to 91.6)§
FEF25-75% −0.69 (−1.63 to 0.38)† Not available
No abnormality, n (%) 90 (62.1%) 102 (70.3%)
Obstruction, n (%) 26 (17.9%) 18 (12.4%)
Reduced FVC, n (%) 29 (20.0%) 25 (17.2%)
Reversibility Testing FEV % Change Reversible, n (%)
Reduced FVC pattern (n = 26) 2.6 (−3.6 to 9.5) 8 (30.8%)
Obstructive pattern (n = 21) 3.3 (−4.3 to 12.1) 7 (33.3%)
All (n = 47) 2.7 (−4.3 to 10.1) 15 (31.9%)
Abbreviations: FEF25–75%, forced expiratory flow at 25%–75%; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GLI, Global Lung Initiative;
IQR, interquartile range.
*Continuous data presented as median (IQR) due to skewed distributions. Includes all traces meeting ATS criteria (grades A and B), n = 145 at baseline, n = 47 for
reversibility testing.
†Median z-score (IQR).
‡Median percentage of predicted (IQR).
§Median percentage (IQR).
Figure 2. Spirometry results overview. Graphs illustrating the degree and distri-
bution of spirometric abnormality. (A) Boxes represent 25th and 75th percen-
tiles, whiskers represent 10th and 90th percentiles, with outliers shown as
individual dots. Upper limit of normal (ULN) and lower limit of normal
(LLN) drawn by dashed line at +1.64 standard deviation (SD) and −1.64 SD
from the mean, respectively. (B) Forced expiratory volume (FEV1) z-score for
all participants as a function of age. Linear regression model is shown as a
solid line. There is a nonsigniﬁcant tendency to reducing FEV1 with increasing
age in this cohort (r2 = 0.026; P = .054). Similar results for forced vital capacity
obtained (results not shown).
Figure 3. Proposed CLD phenotypes. Proportional areas diagram illustrating the
proposed CLD phenotypes, “cough” and “hypoxia”, and their overlap with in-
dividuals with abnormal spirometry. Percentages indicate the proportion of the
entire study population for which spirometry data were available.
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association emerged: individuals reporting cough for more
than 1 month were 2.9 times more likely to have abnormal
spirometry (95% CI, 1.21–7.10).
Microbiological Findings
Sputum was obtained from 32 of 60 participants with
cough, with the remainder unable to expectorate. There
were 6 positive mycobacterial cultures; 2 M tuberculosis
and 4 nontuberculous mycobacteria.
DISCUSSION
This study demonstrates a high burden of symptoms in
children aged 8 to 16 with vertically acquired HIV, consis-
tent with a similar study from Zimbabwe [14]. Over half of
our participants were coughing, wheezy, or breathless.
Within our cohort, there are 2 deﬁnable, common, and in-
dependent phenotypes: children who cough (CLD cough),
and those who have hypoxia at rest or desaturate with sub-
maximal exercise (CLD hypoxia). Neither phenotype was
associated with antiretroviral treatment.
For the CLD-cough phenotype, cough, wheeze, and
functional breathlessness were commonly associated with
each other and also with radiological abnormalities of air-
space shadowing and volume loss where parenchymal lung
disease was likely. Previous treatment for TB was not a sig-
niﬁcant risk factor for this phenotype, and symptoms were
mostly chronic (individuals with symptoms of acute infec-
tion were excluded). Abnormal spirometry was associated
with this phenotype, but there was no preponderance of
obstructive or restrictive types.
The CLD-hypoxia phenotypewas predictably associated
with tachypnoea. There was a suggestion that very low
CD4 counts (<100) predicted hypoxia. Low numbers of in-
dividuals in this group limited our power to detect a differ-
ence. Although not independently associated, there was a
higher than expected rate of ﬁnger clubbing in these
individuals.
Chronic lung disease in these children is likely to be mul-
tifactorial and therefore difﬁcult to clearly deﬁne [15].
Frequent bacterial, mycobacterial, and viral respiratory in-
fections were reported in this population (18.8% of our co-
hort had received treatment for chest infection in the
preceding year), and these can also contribute to bron-
chiectasis. Consistent with underlying bronchiectasis,
there was a high rate of ﬁnger clubbing, reduced lung func-
tion, and radiological abnormalities consistent with bron-
chiectasis. These features are insensitive and nonspeciﬁc for
its diagnosis in isolation [16]. A direct effect of HIV and
chronic inﬂammation of the airways might cause reduced
lung capacities and chronic chest x-ray ﬁndings, including
lymphadenopathy. Findings that the pulmonary microbiota
can be altered in adult HIV, notably for Tropheryma whip-
plei bacteria [17],raise the possibility that these changesmay
reﬂect or drive long-term disease in the airways, including
chronic inﬂammation. High-resolution computerized to-
mography ﬁndings from similar patients in Zimbabwe
that are suggestive of airways disease [18] can represent
the ﬁnal common pathway of many diseases, including post-
infective change, although this is uncommon outside of allo-
geneic transplantation [19]. In our study, the clinical
syndrome of CLD cough including nonreversible spirometry
ﬁndings would be consistent with such pathology [20].
Toro et al [21] demonstrated a high burden of pulmo-
nary lymphoid hyperplasia and lymphoid interstitial pneu-
monitis (LIP) in early life associated with a wide variety of
radiological changes, of which reticular inﬁltrates are most
typical [22]. Early Western cohorts including the P2C2
study noted high rates of LIP and reported chest radiograph
with LIP suggestive changes [23], but this condition has
been almost eliminated with effective ART provision
[24]. Our participants were considerably older than the
usual age of LIP presentation [25], and they started ART
later. In this case, the 2013 WHO guidelines to start all
HIV- positive children under 5 years on ART may improve
rates of CLD in the future.
A Zimbabwean study has shown a high frequency of car-
diac abnormalities and cor pulmonale in adolescents with
vertically transmitted HIV infection [14]. This raises the
possibility that CLD hypoxia might represent pulmonary
vascular disease or interstitial lung disease with secondary
cardiac involvement.
The degree of impairment of lung function is marked
when measured against both internationally used and
locally derived reference ranges. Adult HIV patients in
the United States have higher rates of asthma than the ge-
neral population [26], but the generalizability to our age
group and geography is uncertain. The International
Study of Asthma and Allergies in Childhood (ISAAC)
study [27] did not cover Malawi, but prevalence of wheeze
was 15.9% in English-speaking African countries. In our
study, bronchodilator reversibility was minimal, and rates
of wheeze were similar to regional rates in the general pop-
ulation, suggesting that asthma was unlikely to be a pre-
dominant pathology. The FEV1 improvement after
inhaled bronchodilator was disappointing, and on average
it was indistinguishable from zero. Therefore, it is possible
that even those with >12% increase in FEV1 may represent
bias related to regression to the mean. No participants
found salbutamol helpful at 4 weeks: effective treatment
options are urgently needed.
Within our cohort, there is no strong evidence for clinical-
ly signiﬁcant decline in lung function with age. However,
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this could be confounded by age of ART initiation, and a
longitudinal study to speciﬁcally examine this is in progress.
Declining FEV1 is reported in CLDs such as cystic ﬁbrosis
and chronic obstructive pulmonary disease. In other cohorts
(chronic coughers with bronchiectasis which presented in
childhood), FEV1 declined with age, but this was apparent
only after many years [28]. Some decline may be artefactual
relating to growth and maturation delay, although the sig-
niﬁcant baseline abnormality suggests that earlier life events
have already strongly affected the lung architecture. In any
case, the lack of clinical predictors of lung function abnor-
mality suggests that considerable lung abnormalities,
through intercurrent disease or other effects on lung growth,
may not be identiﬁed unless spirometry is performed. Rates
of reported household biomass fuel use were typical for
many sub-Saharan countries. This important public health
problem may have contributed to reduced lung function in
our population [29].
Our data are limited by (1) the cross-sectional nature of
the study, (2) the lack of total lung volume and transfer fac-
tor measurements, and (3) the absence of noninfected con-
trols. Reversibility studies might be more easily interpreted
with either universal reversibility testing or a control arm,
but this was not possible within our study. We did not have
access to HRCT imaging, echocardiography, or post mor-
tem tissue biopsies, which would deﬁne the pathologies
more clearly, and TB screening was limited by suboptimal
diagnostics.
Prospective studies should examine our deﬁnition of the
2 phenotypes in relation to pathophysiology in a cohort in
which intensive investigation is possible, for example, with
high-resolution computed tomography scanning, echocar-
diography, and, possibly, autopsy studies. If the pheno-
types correlate with disease (we hypothesize cough with
bronchiectasis or bronchiolitis obliterans and hypoxia
with interstitial lung disease), this could be useful to clini-
cians where such investigations are not available.
Longitudinal cohort studies should assess long-term chan-
ge in symptoms and lung function in CLD, and they would
facilitate therapeutic trials of immunomodulation (for ex-
ample, prednisolone in obliterative bronchiolitis) or anti-
microbials (azithromycin in bronchiectasis).
CONCLUSIONS
Widespread evidence of pulmonary disease presented here
adds to the case for treatment of all HIV-infected children
with antiretrovirals irrespective of CD4 count. At the very
least, as a WHO HIV Stage 3 criterion, there should be a
strong emphasis on identifying children with CLD and es-
tablishing early ART in those individuals. For this purpose,
simple clinical deﬁnitions of CLD cough (in the absence of
TB) and CLD hypoxia could be useful to clinicians in
healthcare settings with few resources.
Acknowledgments
We thank all of the participants, their parents and guardians, and clin-
ic staff. We acknowledge the authors of CFQ-R: Alexandra
L. Quittner, Anne Buu, Marc Watrous, and Melissa A. Davis.
Author contributions. J. R., S. J. R., T. M., E. L. C., and R. A. F. con-
tributed to conception and design; B. O., J. J. v. O., and S. A. provided
clinical advice; and E. L. W. provided statistical support. All authors
contributed to writing the article and approved the ﬁnal version.
Financial support. T. M. was funded by the Commonwealth scholar-
ship, with research costs from a grant fom Helse Nord Northern
Norway Regional Health Authority. E. L. C., R. A. F., and J. R. are
supported by Wellcome Trust Fellowships (Senior Fellowship in
Clinical Sciences WT091769, Career Development Fellowship
WT095878 and Clinical PhD Fellowship 086756/B/08/Z,
respectively).
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of
Potential Conﬂicts of Interest.
Supplementary Data
Supplementary materials are available at the Journal of
The Pediatric Infectious Diseases Society online (http://
jpids.oxfordjournals.org).
References
1. UNAIDS. 2014 progress report on the Global Plan. Geneva:
UNAIDS; 2013.
2. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antire-
troviral therapy among HIV-infected children in sub-Saharan
Africa. Lancet Infect Dis 2008; 8:477–89.
3. Ferrand RA, Bandason T, Musvaire P, et al. Causes of acute
hospitalization in adolescence: burden and spectrum of HIV-
related morbidity in a country with an early-onset and severe
HIV epidemic: a prospective survey. PLoS Med 2010; 7:
e1000178.
4. Graham SM.Non-tuberculosis opportunistic infections and other
lung diseases in HIV-infected infants and children. Int J Tuberc
Lung Dis 2005; 9:592–602.
5. Lepage P, Van de Perre P, Van Vliet G, et al. Clinical and endocri-
nologic manifestations in perinatally human immunodeﬁciency
virus type 1–Infected children aged 5 years or older. Am J Dis
Child 1991; 145:1248–51.
6. Desai SR, Copley SJ, Barker RD, et al. Chest radiography patterns
in 75 adolescents with vertically-acquired human immunodeﬁ-
ciency virus (HIV) infection. Clin Radiol 2011; 66:257–63.
7. de Onis M, Onyango AW, Borghi E, et al. Development of a
WHO growth reference for school-aged children and adolescents.
Bull World Health Organ 2007; 85:660–7.
8. Modi AC, Quittner AL. Validation of a disease-speciﬁc measure
of health-related quality of life for children with cystic ﬁbrosis.
J Pediatr Psychol 2003; 28:535–45.
9. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of
spirometry. Eur Respir J 2005; 26:319–38.
8 Mwalukomo et al
10. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic ref-
erence values for spirometry for the 3-95-yr age range: the
global lung function 2012 equations. Eur Respir J 2012; 40:
1324–43.
11. Zverev Y, Gondwe M. Ventilatory capacity indices in Malawian
children. East Afr Med J 2001; 78:14–8.
12. Victora CG,Huttly SR, Fuchs SC, OlintoMT. The role of concep-
tual frameworks in epidemiological analysis: a hierarchical ap-
proach. Int J Epidemiol 1997; 26:224–7.
13. Ferrand RA, Munaiwa L, Matsekete J, et al. Undiagnosed HIV
infection among adolescents seeking primary health care in
Zimbabwe. Clin Infect Dis 2010; 51:844–51.
14. Miller RF, Kaski JP, Hakim J, et al. Cardiac disease in adolescents
with delayed diagnosis of vertically acquired hiv infection. Clin
Infect Dis 2013; 56:576–82.
15. Weber HC, Gie RP, Cotton MF. The challenge of chronic lung
disease in HIV-infected children and adolescents. J Int AIDS
Soc 2013; 16:18633.
16. Rossi UG, Owens CM. The radiology of chronic lung disease in
children. Arch Dis Child 2005; 90:601–7.
17. Lozupone C, Cota-Gomez A, Palmer BE, et al. Widespread colo-
nization of the lung by Tropheryma whipplei in HIV infection.
Am J Respir Crit Care Med 2013; 187:1110–7.
18. Lynch JP 3rd, Weigt SS, DerHovanessian A, et al. Obliterative
(constrictive) bronchiolitis. Semin Respir Crit Care Med 2012;
33:509–32.
19. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bron-
chiolitis. N Engl J Med 2014; 370:1820–8.
20. Aguerre V, Castanos C, Pena HG, et al. Postinfectious bronchio-
litis obliterans in children: clinical and pulmonary function ﬁnd-
ings. Pediatr Pulmonol 2010; 45:1180–5.
21. Toro AA, Altemani AA, Zanardi VA, et al. Lung disease features
in Brazilian children with HIV infection before HAART era.
J Trop Pediatr 2006; 52:360–8.
22. Pitcher RD, Beningﬁeld SJ, ZarHJ. Chest radiographic features of
lymphocytic interstitial pneumonitis in HIV-infected children.
Clin Radiol 2010; 65:150–4.
23. Shearer WT, Lipshultz SE, Easley KA, et al. Alterations in cardiac
and pulmonary function in pediatric rapid human immunodeﬁ-
ciency virus type 1 disease progressors. Pediatric Pulmonary and
Cardiovascular Complications of Vertically Transmitted Human
Immunodeﬁciency Virus Study Group. Pediatrics 2000; 105:e9.
24. Dufour V, Wislez M, Bergot E, et al. Improvement of sympto-
matic human immunodeﬁciency virus-related lymphoid intersti-
tial pneumonia in patients receiving highly active antiretroviral
therapy. Clin Infect Dis 2003; 36:e127–30.
25. Sharland M, Gibb DM, Holland F. Respiratory morbidity from
lymphocytic interstitial pneumonitis (LIP) in vertically acquired
HIV infection. Arch Dis Child 1997; 76:334–6.
26. Gingo MR, Wenzel SE, Steele C, et al. Asthma diagnosis and air-
way bronchodilator response in HIV-infected patients. J Allergy
Clin Immunol 2012; 129:708–14.
27. Ait-Khaled N, Odhiambo J, Pearce N, et al. Prevalence of symp-
toms of asthma, rhinitis and eczema in 13- to 14-year-old children
in Africa: the International Study of Asthma and Allergies in
Childhood Phase III. Allergy 2007; 62:247–58.
28. King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult
bronchiectasis: onset of productive cough in childhood and adult-
hood. COPD 2009; 6:130–6.
29. Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from
household air pollution in low and middle income countries.
Lancet Respir Med 2014; 2:823–60.
Lung Health in Vertically Acquired HIV 9
